De Gruyter extends its reach in Hungary
The Hungarian Electronic Information Service National Programme (EISZ), and De Gruyter have signed an agreement to provide access to De Gruyter journal collections to the consortium, which also provides authors affiliated to the subscribing institutions with an open access publishing option in both hybrid and “gold” De Gruyter open access journals with no further costs. The subscribing institutions in 2018 are Eötvös Loránd University, Károli Gáspár University of the Reformed Church, the Library and Information Centre of the Hungarian Academy of Sciences, the Lutheran Theological University, the Pentecostal Theological College, and Pázmány Péter Catholic University. “We are pleased to have come to an agreement with such a renowned publisher as De Gruyter, and to have formed a consortium under the umbrella of EISZ. This forward-thinking agreement will not only provide access to the world-class research published by De Gruyter but also increase the visibility of Hungarian research. This demonstrates that open access is a priority for both parties, and we are delighted to work together in order to serve the needs of the Hungarian scientific community,” said István Monok, General Director of the Library and Information Centre of the Hungarian Academy of Sciences, and President of the EISZ Programme Board. “We look forward to cooperating with the Hungarian Electronic Information Service...
Peng Li, Rongmei Wang, Hongchao Jiao, Xiaojuan Wang, Jingpeng Zhao, Hai Lin
Chun-Chieh Huang, Raghuvaran Narayanan, Noah Warshawsky, Sriram Ravindran
Org. Biomol. Chem., 2018, Accepted Manuscript DOI: 10.1039/C8OB00979A, CommunicationShuhei Kusano, Sae Konishi, Yuji Yamada, Osamu Hayashida Three series of water-soluble anthracene-appended benzoxaboroles 1a-c were developed; their binding affinity toward cis-1,2-diols was explored by conventional fluorescence titrations to demonstrate the role of benzoxaborole as a general recognition... The content of this RSS Feed (c) The Royal Society of Chemistry
Org. Biomol. Chem., 2018, Advance Article DOI: 10.1039/C8OB01015C, CommunicationClaire L. Jarvis, Neyra M. Jemal, Spencer Knapp, Daniel Seidel A new preparation of [small delta]-lactams is reported. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
Org. Biomol. Chem., 2018, Advance Article DOI: 10.1039/C8OB00942B, PaperXiangqing Chang, Xiongfei Zhang, Zhiwei Chen The atom-economical characteristics, mild conditions, simple operation and broad substrate scope demonstrated the synthetic value of this protocol. To cite this article before page numbers are assigned, use the DOI form of citation above. The content of this RSS Feed (c) The Royal Society of Chemistry
DISCUSSION: Current WHO guidelines support the use of fluoroquinolones (first-line), β-lactams (second-line) and cephalosporins (second-line) which accords with currently available evidence and other international guidelines, and there is no strong evidence for changing this guidance. Azithromycin is appropriate as a second-line therapy in regions where the rate of non-susceptibility of ciprofloxacin is known to be high, and research suggests that, from a cardiac point of view, azithromycin is safer than other macrolide antibiotics. Cefixime is also a reasonable alternative, although its use must be weighed against th...
Conclusion Further pragmatic trials are required to optimise management of hospitalised children with severe and very severe pneumonia. PMID: 29790844 [PubMed - in process]
Authors: Ashorn P PMID: 29790843 [PubMed - in process]
Conclusions Current WHO guidelines supporting the use of gentamicin and penicillin for hospital-based patients or gentamicin (IM) and amoxicillin (oral) when referral to a hospital is not possible are in accordance with currently available evidence and other international guidelines, and there is no strong evidence to change this. The benefit of a cephalosporin alone or in combination as a second-line therapy in regions with known high rates of non-susceptibility is not well established. Further research into hospital-acquired sepsis in neonates and children is required. PMID: 29790842 [PubMed - in process]
Conclusions In view of the changing non-susceptibility rates worldwide, empirical therapy for cholera infection in paediatric patients should be changed to single-dose azithromycin (20 mg/kg), a safe and effective medication with ease of administration. Erythromycin (12.5 mg/kg four times daily for 3 days) exhibits similar bacteriological and clinical success and should be listed as a second-line therapy. Fluid resuscitation remains the cornerstone of management of paediatric cholera infection, and prevention of infection by promoting access to clean water and sanitation is paramount. PMID: 29790841 [PubMed - in process]